Hormone replacement therapy – where are we now?

References

• Women’s Health Concern. Complementary/alternative therapies for postmenopausal women. 2020. Available from: https://www.womens-health-concern.org/help-and-advice/factsheets/complementaryalternative-therapies-menopausal-women/
   Google Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978
   Google Scholar
• North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–74
   PubMed Web of Science ®Google Scholar
• Salpeter S, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;(3):CD002229
   Google Scholar
• Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42–52
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ 2012;345:e6409
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Stagnitti MN, Lefkowitz D. Trends in hormone replacement therapy drugs utilization and expenditures for adult women in the U.S. Civilian Noninstitutionalized Population, 2001–2008. Medical Expenditure Panel Survey, Statistical Brief #347, US Agency for Healthcare Research and Quality, November 2011
   Google Scholar
• Centers for Disease Control. Health U.S. Resident population, by age, sex, race, and Hispanic origin: United States, selected years 1950–2016. 2017. Available from: https://www.cdc.gov/nchs/data/hus/2017/001.pdf
   Google Scholar
• Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583–8
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
   PubMed Web of Science ®Google Scholar
• Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause 2018;25:375–9
   PubMed Web of Science ®Google Scholar
• Wang C, O'Neill SM, Rothrock N, et al. Comparison of risk perceptions and beliefs across common chronic diseases. Prev Med 2009;48:197–202
   PubMed Web of Science ®Google Scholar
• Covello VT, Peters RG. Women's perceptions of the risks of age-related diseases, including breast cancer: reports from a 3-year research study. Health Commun 2002;14:377–95
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Farmer RDT. HRT and breast cancer: a million women ride again. Climacteric 2020;23:226–8
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Women's health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the women’s health initiative Investigators. Risks and benefits of estrogen plus progestin for healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA 2020;324:369–80
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s health initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159–68
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences (CIOMS) Working Groups III and IV. Guidelines for Preparing Core Clinical-Safety Information on Drugs, Second Edition. Geneva, 1999. ISBN 92 9036 070 4
   Google Scholar
• Women’s Health Initiative Investigators. Protocol for the clinical trial and observational study components. Available from: https://www-whi-org.s3.us-west-2.amazonaws.com/wp-content/uploads/Protocol-1993-2005.pdf
   Google Scholar
• Langer RD. On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause. Climacteric 2010;13:303–6
   PubMed Web of Science ®Google Scholar
• Langer RD. The evidence base for HRT: what can we believe? Climacteric 2017;20:91–6
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: The modulating effect of statins. Atherosclerosis 2006;189:76–82
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, ELITE Research Group, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016–22
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density, results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;276:1389–96
   PubMed Web of Science ®Google Scholar
• Cauley J, Robbins J, Chen Z. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729–38
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res 2006;21:817–28
   PubMed Web of Science ®Google Scholar
• Langer RD, Criqui MH, Barrett-Connor EL, Denenberg JO, Fronek A. Estrogen is associated with greater arterial flow velocities in older women. Can J Cardiol 1997;13:330B
   Google Scholar
• Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538–54
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459–61
   PubMed Web of Science ®Google Scholar
• Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829–34
   PubMed Web of Science ®Google Scholar
• Brinton RD, Chen S, Montoya M, Hsieh D, Minaya J. The estrogen replacement therapy of the Women’s Health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer’s disease. Maturitas 2000;34:S35–S52
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kapoor E, Moyer AM, Hodis HN, Miller VM. Statin therapy: does sex matter? Menopause 2019;26:1425–35
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30
   PubMed Web of Science ®Google Scholar
• Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001;10:971–81
   PubMedGoogle Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Pyörälä K, Cook TJ, 4S Group, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771–7
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Tang MTC, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med 2013;173:1629–37
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728–37
   PubMed Web of Science ®Google Scholar
• Bhuriya R, Singh M, Molnar J, Arora R, Khosla S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010;142:213–17
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: Comparative risks. J Am Geriatr Soc 2013;61:1011–18
   PubMed Web of Science ®Google Scholar
• Sheu Y, Lanteigne A, Stürmer T, Pate V, Azrael D, Miller M. SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj Prev 2015;21:397–403
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213–17
   PubMed Web of Science ®Google Scholar
• Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517–21
   PubMed Web of Science ®Google Scholar
• Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429–32
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA 2003;289:2651–62
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's Health Initiative Memory Study. JAMA 2004;291:2947–58
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 2005;192:387–93
   PubMed Web of Science ®Google Scholar
• Humana formulary accessed 08.14.20. Available from: https://drugpricing.humana.com/drug-search
   Google Scholar
• Baber RJ, Panay N, Fenton A. IMS 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Constantine GD, Kessler G, Graham S, et al. Increased incidence of endometrial cancer following the Women's Health Initiative: an assessment of risk factors. J Womens Health (Larchmt) 2019;28:237–43
   PubMed Web of Science ®Google Scholar
• Scarabin P-Y, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the Women's Health Initiative Observational Study. Menopause 2014;21:260–6
   PubMed Web of Science ®Google Scholar
• Simon JA, Laliberté F, Duh MS, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 2016;23:600–10
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1–9
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125–34
   PubMed Web of Science ®Google Scholar
• Lobo RA, Davis SR, De Villiers TJ, et al. Prevention of diseases after menopause. Climacteric 2014;17:540–56
   PubMed Web of Science ®Google Scholar
• Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause 2013;20:1098–105
   PubMed Web of Science ®Google Scholar